- Conditions
- Neurogenic Orthostatic Hypotension, Multiple System Atrophy (MSA) With Orthostatic Hypotension, Pure Autonomic Failure, Parkinson Disease, Hypotension, Orthostatic, Orthostatic Hypotension, Pure Autonomic Failure With Orthostatic Hypotension, Parkinson Disease With Orthostatic Hypotension
- Interventions
- TD-9855, Placebo
- Drug
- Lead sponsor
- Theravance Biopharma
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 6
- States / cities
- Long Beach, California • Farmington Hills, Michigan • Berlin, New Jersey + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 77
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- B-Lymphoid Malignancies, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Non-hodgkin Lymphoma
- Interventions
- Fludarabine, Cyclophosphamide, Mesna, iC9/CAR.19/IL15-Transduced CB-NK Cells, AP1903
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 7 Years to 80 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Scleroderma, Systemic Sclerosis
- Interventions
- Fludarabine, Cyclophosphamide, Thymoglobulin, Leukapheresis, Self bone marrow transplant
- Drug · Procedure
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Multiple System Atrophy
- Interventions
- AAV2-GDNF gene therapy, Sham (Placebo) Surgery
- Biological · Procedure
- Lead sponsor
- Brain Neurotherapy Bio, Inc.
- Industry
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 7
- States / cities
- Irvine, California • Boca Raton, Florida • Boston, Massachusetts + 4 more
- Conditions
- Multiple System Atrophy
- Interventions
- intravenous immunoglobulin (IVIg)
- Drug
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- Multiple System Atrophy
- Interventions
- Not listed
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 29 participants
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Neurologic Disorders, Nervous System Diseases, Neurodegenerative Diseases, Neurological Disorders, Stroke, Traumatic Brain Injury, Cadasil, Chronic Traumatic Encephalopathy, Cerebral Infarction, Cerebral Ischemia, Cerebral Stroke, Cerebral Hemorrhage, Parkinson, Multi-System Degeneration, MSA - Multiple System Atrophy, Progressive Supranuclear Palsy, ALS, Amyotrophic Lateral Sclerosis, Neuropathy, Diabetic Neuropathies, Alzheimer Disease, Dementia, Frontotemporal Dementia, Lewy Body Disease, Cognitive Impairment, Lewy Body Variant of Alzheimer Disease
- Interventions
- Intravenous and Intranasal BMSC
- Procedure
- Lead sponsor
- MD Stem Cells
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 2
- States / cities
- Westport, Connecticut • Coral Springs, Florida
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Lymphoma
- Interventions
- Busulfan, Fludarabine, Total-body irradiation, Cyclophosphamide, Melphalan, PBSC Hematopoietic Stem Cell Transplantation (HSCT), Bone Marrow Hematopoietic Stem Cell Transplantation, Post-transplant Cyclophosphamide, Mesna, Tacrolimus, Mycophenolate Mofetil, Patient-Reported Outcomes
- Drug · Radiation · Procedure + 1 more
- Lead sponsor
- Center for International Blood and Marrow Transplant Research
- Network
- Eligibility
- 1 Year and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 39
- States / cities
- Duarte, California • San Francisco, California • Stanford, California + 28 more
- Conditions
- Lymphoma
- Interventions
- Radiation Therapy, Dexamethasone, Etoposide phosphate, Ifosfamide, Mesna, Carboplatin
- Radiation · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2034
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple System Atrophy
- Interventions
- Foralumab Nasal
- Drug
- Lead sponsor
- Tiziana Life Sciences LTD
- Industry
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Breast Cancer
- Interventions
- etoposide, ifosfamide, topotecan hydrochloride, peripheral blood stem cell transplantation
- Drug · Procedure
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years to 64 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2001
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy, Multiple System Atrophy, Dopamine Beta Hydroxylase Deficiency
- Interventions
- Droxidopa, Placebo
- Drug
- Lead sponsor
- Chelsea Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 39 more
- Conditions
- Parkinson's Disease, Multiple System Atrophy, Parkinson Variant, Multiple System Atrophy
- Interventions
- This is an observational study.
- Other
- Lead sponsor
- AskBio Inc
- Industry
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 7
- States / cities
- Irvine, California • Boca Raton, Florida • Boston, Massachusetts + 4 more
- Conditions
- Leukemia
- Interventions
- Rituximab, Imatinib, Cyclophosphamide, Doxorubicin, Mesna, VSLI, Solu-Medrol, Methotrexate, Ara-C, G-CSF, Pegfilgrastim, Dexamethasone
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hodgkin's Lymphoma
- Interventions
- Panobinostat, Ifosfamide, Mesna, Carboplatin, Etoposide, Pegfilgrastim
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension
- Interventions
- ampreloxetine
- Drug
- Lead sponsor
- Theravance Biopharma
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 13
- States / cities
- Colorado Springs, Colorado • Boca Raton, Florida • Port Charlotte, Florida + 10 more
- Conditions
- Rapid Eye Movement Sleep Behavior Disorder
- Interventions
- Not listed
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 35 Years to 70 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple System Atrophy - Parkinsonian Subtype (MSA-P), Multiple System Atrophy - Cerebellar Subtype (MSA-C)
- Interventions
- Not listed
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- MSA
- Interventions
- Autologous Mesenchymal Stem Cells
- Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Leukemia, Lymphocytic, Acute, Leukemia, Myelocytic, Acute, Leukemia, Myeloid, Chronic, Lymphoma, Non-Hodgkin
- Interventions
- Expanded allogeneic cord blood (CB), One Unmanipulated and One Expanded Cord Blood Unit, Rituxan, Melphalan, Thiotepa, Fludarabine, Cyclophosphamide, Mesna, Total body irradiation (TBI)
- Procedure · Drug · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 1 Month to 80 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Progressive Supranuclear Palsy, Parkinson Disease, MSA - Multiple System Atrophy
- Interventions
- Not listed
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Boston, Massachusetts
- Conditions
- Multiple System Atrophy (MSA), Healthy Adult, Parkinson Disease
- Interventions
- [¹⁸F]MODAG-009 PET imaging
- Drug
- Lead sponsor
- MODAG GmbH
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy, Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
- Interventions
- Placebo, Droxidopa
- Drug
- Lead sponsor
- Chelsea Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 14
- States / cities
- Huntsville, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 11 more
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy
- Interventions
- Ampreloxetine, Placebo
- Drug
- Lead sponsor
- Theravance Biopharma
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 26
- States / cities
- Scottsdale, Arizona • Fountain Valley, California • La Jolla, California + 21 more